1. Which of the following agents is a tumor necrosis factor-alpha inhibitor?

2. The mechanism of action of sarilumab is:

3. What is the treatment target for rheumatoid arthritis?

4. BT is a 42-year-old female with a 5-year history of rheumatoid arthritis. She was initially treated with methotrexate but discontinued therapy due to elevated liver enzymes. Six months ago, she started treatment with infliximab but has not achieved a sufficient response. What would be the most appropriate treatment choice for monotherapy at this time?

5. Patients receiving tumor necrosis factor-alpha inhibitors for rheumatoid arthritis should receive education on which of the following?

6. Which agent for rheumatoid arthritis is associated with an increased risk of herpes zoster infection?

7. Before initiation of tumor necrosis factor-alpha therapy, pharmacists should ensure that patients have been screened for all of the following EXCEPT:

8. LG is a 54-year-old male with rheumatoid arthritis. His treatment history includes hydroxychloroquine, methotrexate, adalimumab, and golimumab. He presents with multiple swollen joints and overall worsening of symptoms. What would be the most appropriate treatment option for this patient?

9. HT is a 67-year-old female about to begin therapy with abatacept for rheumatoid arthritis (RA). During a medication therapy management appointment, she reports being unsure about her vaccine history. What would be the most appropriate course of action for HT?

10. Due to an increased risk of disease and complications, screening recommendations for which of the following comorbidities should begin at an earlier age for patients with rheumatoid arthritis (RA) than for patients without RA?

« Return to Activity